Callan Family Office LLC Acquires New Shares in Takeda Pharmaceutical Co. $TAK

Callan Family Office LLC acquired a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 47,762 shares of the company's stock, valued at approximately $738,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter worth about $37,000. Farther Finance Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after buying an additional 1,045 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after buying an additional 2,411 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after buying an additional 1,296 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Takeda Pharmaceutical in the first quarter worth about $125,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $13.72 on Tuesday. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The stock has a market capitalization of $43.64 billion, a PE ratio of 45.72 and a beta of 0.21. The stock has a 50-day simple moving average of $14.85 and a 200 day simple moving average of $14.78.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The business had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TAK. Zacks Research cut Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 21st. Weiss Ratings reissued a "hold (c)" rating on shares of Takeda Pharmaceutical in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.